Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Adipose tissue is an active endocrine organ that secretes various metabolically important substances including adipokines, which represent a link between insulin resistance and nonalcoholic steatohepatitis (NASH). The factors responsible for the progression from simple steatosis to steatohepatitis remain elusive, but adipokine imbalance may play a pivotal role. We evaluated the expressions of adipokines such as visfatin, adipocyte-fatty-acid-binding protein (A-FABP), and retinol-binding protein-4 (RBP-4) in serum and tissue. The aim was to discover whether these adipokines are potential predictors of NASH. Methods: Polymerase chain reaction, quantification of mRNA, and Western blots encoding A-FABP, RBP-4, and visfatin were used to study tissue samples from the liver, and visceral and subcutaneous adipose tissue. The tissue samples were from biopsy specimens obtained from patients with proven NASH who were undergoing laparoscopic cholecystectomy due to gallbladder polyps. Results: Patients were classified into two groups: NASH, n =10 and non-NASH, n =20 according to their nonalcoholic fatty liver disease Activity Score. Although serum A-FABP levels did not differ between the two groups, the expressions of A-FABP mRNA and protein in the visceral adipose tissue were significantly higher in NASH group than in non-NASH group (104.34 vs. 97.05, P<0.05, and 190.01 vs. 95.15, P<0.01, respectively). Furthermore, the A-FABP protein expression ratio between visceral adipose tissue and liver was higher in NASH group than in non-NASH group (4.38 vs. 1.64, P<0.05). Conclusions: NASH patients had higher levels of A-FABP expression in their visceral fat compared to non-NASH patients. This differential A-FABP expression may predispose patients to the progressive form of NASH. (Clin Mol Hepatol 2012;18:279-286)
Abstract
Background/Aims: Adipose tissue is an active endocrine organ that secretes various metabolically important substances including adipokines, which represent a link between insulin resistance and nonalcoholic steatohepatitis (NASH). The factors responsible for the progression from simple steatosis to steatohepatitis remain elusive, but adipokine imbalance may play a pivotal role. We evaluated the expressions of adipokines such as visfatin, adipocyte-fatty-acid-binding protein (A-FABP), and retinol-binding protein-4 (RBP-4) in serum and tissue. The aim was to discover whether these adipokines are potential predictors of NASH. Methods: Polymerase chain reaction, quantification of mRNA, and Western blots encoding A-FABP, RBP-4, and visfatin were used to study tissue samples from the liver, and visceral and subcutaneous adipose tissue. The tissue samples were from biopsy specimens obtained from patients with proven NASH who were undergoing laparoscopic cholecystectomy due to gallbladder polyps. Results: Patients were classified into two groups: NASH, n =10 and non-NASH, n =20 according to their nonalcoholic fatty liver disease Activity Score. Although serum A-FABP levels did not differ between the two groups, the expressions of A-FABP mRNA and protein in the visceral adipose tissue were significantly higher in NASH group than in non-NASH group (104.34 vs. 97.05, P<0.05, and 190.01 vs. 95.15, P<0.01, respectively). Furthermore, the A-FABP protein expression ratio between visceral adipose tissue and liver was higher in NASH group than in non-NASH group (4.38 vs. 1.64, P<0.05). Conclusions: NASH patients had higher levels of A-FABP expression in their visceral fat compared to non-NASH patients. This differential A-FABP expression may predispose patients to the progressive form of NASH. (Clin Mol Hepatol 2012;18:279-286)
참고문헌 (26)
- Tsochatzis EA, "Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy", Mediators Inflamm, 2009, pp.831670~ (2009)
- Neuschwander-Tetri BA, "Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference", Hepatology, 37, pp.1202~1219 (2003)
- Wieckowska A, "Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future", Hepatology, 46, pp.582~589 (2007)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- van der Poorten D, "Visceral fat: a key mediator of steatohepatitis in metabolic liver disease", Hepatology, 48, pp.449~457 (2008)
- Lafontan M, "Do regional differences in adipocyte biology provide new pathophysiological insights?", Trends Pharmacol Sci, 24, pp.276~283 (2003)
- Bergman RN, "Why visceral fat is bad: mechanisms of the metabolic syndrome", Obesity, 14(Suppl), pp.16S~19S (2006)
- Day CP, "Steatohepatitis: a tale of two “hits”?", Gastroenterology, 114, pp.842~845 (1998)
- Lewis JR, "Nonalcoholic fatty liver disease: a review and update", Dig Dis Sci, 55, pp.560~578 (2010)
- Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
- Feldstein AE, "Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway", Hepatology, 40, pp.185~194 (2004)
- Cao H, "Regulation of Metabolic responses by adipocyte", macrophage fatty acid-binding proteins in leptin-deficient mice, 2006, pp.55, 1915~1922[DOI]
- Fukuhara A, "Visfatin: a protein secreted by visceral fat that mimics the effects of insulin", Science, 307, pp.426~430 (2005)
- Filippatos TD, "Increased plasma visfatin levels in subjects with the metabolic syndrome", Eur J Clin Invest, 38, pp.71~72 (2008)
- Oki K, "Circulating visfatin level is correlated with inflammation, but not with insulin resistance", Clin Endocrinol (Oxf), 67, pp.796~800 (2007)
- Jarrar MH, "Adipokines and cytokines in non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 27, pp.412~421 (2008)
- Aller R, "Influence of visfatin on histopathological changes of nonalcoholic fatty liver disease", Dig Dis Sci, 54, pp.1772~1777 (2009)
- Yang Q, "Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes", Nature, 436, pp.356~362 (2005)
- Klöting N, "Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intraabdominal fat mass", Cell Metab, 6, pp.79~87 (2007)
- Stefan N, "High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans", Diabetes Care, 30, pp.1173~1178 (2007)
- Bahr MJ, "Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis", Clin Endocrinol (Oxf), 70, pp.60~65 (2009)
- Furuhashi M, "Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets", Nat Rev Drug Discov, 7, pp.489~503 (2008)
- Maeda K, "Adipocyte", macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes, 2005, pp.1, 107~119
- Furuhashi M, "Adipocyte", macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice, 2008, pp.118, 2640~2650
- Kim YC, "Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects", J Nutr Biochem, 22, pp.289~292 (2011)
- Milner KL, "Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease", Hepatology, 49, pp.1926~1934 (2009)